UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abstract P5-16-14: NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-16-14

2017

Volltextzugriff (PDF)

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Breast cancer research and treatment, 2010-08, Vol.123 (1), p.9-24

2010

Volltextzugriff (PDF)

Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013

Cancer epidemiology, 2016-10, Vol.44, p.186-194

2016

Volltextzugriff (PDF)

Abstract P1-06-04: Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-04

2018

Volltextzugriff (PDF)

Abstract P1-06-02: Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-02

2018

Volltextzugriff (PDF)

Abstract OT1-05-02: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-05-02-OT1-05-02

2019

Volltextzugriff (PDF)

Abstract OT1-06-01: OPTIMA: A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT1-06-01-OT1-06-01

2018

Volltextzugriff (PDF)

Abstract PD2-07: 10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.PD2-07-PD2-07

2017

Volltextzugriff (PDF)

Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S4-S4-06

2016

Volltextzugriff (PDF)

Abstract P2-08-29: Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-08-29

2016

Volltextzugriff (PDF)

Abstract OT3-02-02: ROSCO: A randomised phase III, stratified CEP17/TOP2A biomarker trial of neo-adjuvant 5-flourouracil, epirubicin and cyclophosphamide vs docetaxel and cyclophosphamide chemotherapy

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT3-02-02-OT3-02-02

2016

Volltextzugriff (PDF)

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

Annals of oncology, 2005-07, Vol.16 (7), p.1123-1132

2005

Volltextzugriff (PDF)

Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT2-3-01-OT2-3-01

2013

Volltextzugriff (PDF)

Abstract PD10-03: Is 5-50% of Amplified Cells a Suitable Cut Off To Define Heterogeneous Amplification of the HER2 Oncogene?

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.PD10-03-PD10-03

2010

Volltextzugriff (PDF)

Abstract P4-11-05: Acute and Late Toxicity Results from the SECRAB Trial: The Optimal SEquencing of Adjuvant Chemotherapy (CT) and RAdiotherapy (RT) in Early Breast Cancer (EBC)

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P4-P4-11-05

2010

Volltextzugriff (PDF)

Abstract P3-10-04: An Integration of Biological and Pathological Marker Panel in the TEAM Pathology Sub-Study: The Impact of Different Parameters on Risk Estimation of Relapse at Both 2.75 and 5 Years

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P3-P3-10-04

2010

Volltextzugriff (PDF)

PCN15 SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ ADVANCED OR METASTATIC BREAST CANCER (MBC)

Value in health, 2010, Vol.13 (7), p.A253-A253

2010

Volltextzugriff (PDF)

Abstract S2-4: Final Results of a Prospectively Planned Biomarker Analysis: HER1-3 as Predictive Markers of Benefit from Early Treatment with Aromatase Inhibitors Versus Tamoxifen in the TEAM Pathology Sub-Study

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.S2-S2-4

2010

Volltextzugriff (PDF)

Monitoring the introduction of new drugs – Herceptin to cardiotoxicity

Clinical medicine (London, England), 2006-09, Vol.6 (5), p.478-481

2006

Volltextzugriff (PDF)

Optimal Motivation for Talent Development

Journal for the education of the gifted, 2000-12, Vol.23 (2), p.187-216

Rea, Dan W.

2000

Volltextzugriff (PDF)

Metastatic breast cancer response after Exemestane withdrawal: a case report

Breast (Edinburgh), 2004-02, Vol.13 (1), p.66-68

2004

Volltextzugriff (PDF)

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Cancer chemotherapy and pharmacology, 2004-04, Vol.53 (4), p.341-348

2004

Volltextzugriff (PDF)

Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide

Clinical medicine (London, England), 2007-01, Vol.7 (1), p.88-89

2007

Volltextzugriff (PDF)

A novel method for controlling the pepsin digestion of antibodies

Journal of immunological methods, 1993-01, Vol.157 (1), p.165-173

1993

Volltextzugriff (PDF)

College Students' Perceptions of Academic Success: An Examination of Motivational Orientation

Teaching of psychology, 1991-04, Vol.18 (2), p.109-111

Rea, Dan W.

1991

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(18)
Humans
(12)
Female
(11)
Biological And Medical Sciences
(9)
Medical Sciences
(8)
Aged
(7)
Adult
(6)
Oncology
(6)
Aged, 80 And Over
(5)
Breast Cancer
(5)
Breast Neoplasms - Drug Therapy
(5)
Male
(5)
Middle Aged
(5)
Breast Neoplasms - Pathology
(4)
Incidence
(4)
Social Sciences
(4)
Tumors
(4)
Animals
(3)
Antineoplastic Agents - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract P5-16-14: NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013

Abstract P1-06-04: Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading?

Abstract P1-06-02: Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree?

Abstract OT1-05-02: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Abstract OT1-06-01: OPTIMA: A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer

Abstract PD2-07: 10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial

Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

Abstract P2-08-29: Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial

Abstract OT3-02-02: ROSCO: A randomised phase III, stratified CEP17/TOP2A biomarker trial of neo-adjuvant 5-flourouracil, epirubicin and cyclophosphamide vs docetaxel and cyclophosphamide chemotherapy

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ

Abstract PD10-03: Is 5-50% of Amplified Cells a Suitable Cut Off To Define Heterogeneous Amplification of the HER2 Oncogene?

Abstract P4-11-05: Acute and Late Toxicity Results from the SECRAB Trial: The Optimal SEquencing of Adjuvant Chemotherapy (CT) and RAdiotherapy (RT) in Early Breast Cancer (EBC)

Abstract P3-10-04: An Integration of Biological and Pathological Marker Panel in the TEAM Pathology Sub-Study: The Impact of Different Parameters on Risk Estimation of Relapse at Both 2.75 and 5 Years

PCN15 SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ ADVANCED OR METASTATIC BREAST CANCER (MBC)

Abstract S2-4: Final Results of a Prospectively Planned Biomarker Analysis: HER1-3 as Predictive Markers of Benefit from Early Treatment with Aromatase Inhibitors Versus Tamoxifen in the TEAM Pathology Sub-Study

Monitoring the introduction of new drugs – Herceptin to cardiotoxicity

Optimal Motivation for Talent Development

Metastatic breast cancer response after Exemestane withdrawal: a case report

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide

A novel method for controlling the pepsin digestion of antibodies

College Students' Perceptions of Academic Success: An Examination of Motivational Orientation

Suchergebnisse filtern